Aura Biosciences Q1 2023 Earnings Report
Key Takeaways
Aura Biosciences reported its Q1 2023 financial results, highlighting FDA guidance supporting their global Phase 3 trial and the completion of enrollment in their Phase 2 trial. The company's cash and cash equivalents totaled $173.5 million, expected to fund operations into 2025.
FDA provided guidance supporting the global Phase 3 trial in early-stage choroidal melanoma.
Enrollment is complete in the Phase 2 trial in choroidal melanoma using suprachoroidal route of administration.
Planning to initiate a potentially registration-enabling Phase 3 clinical trial in 1H 2023 to evaluate the safety and efficacy of Belzupacap Sarotalocan (bel-sar) for the first-line treatment of adult patients with early-stage choroidal melanoma.
As of March 31, 2023, Aura had cash and cash equivalents and marketable securities totaling $173.5 million.
Aura Biosciences
Aura Biosciences
Forward Guidance
Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2025.